Current Report Filing (8-k)
August 14 2017 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
_______________________
Date of Report: August 10, 2017 (Date of
earliest event reported)
CAPSTONE THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-21214
|
|
86-0585310
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1275 West Washington Street, Suite 101, Tempe, Arizona
|
|
85281
|
(Address
of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(602) 286-5520
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[ ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Section 4 –
Matters Related to Accountants and Financial Statements
|
Item 4.01
|
Changes in Registrant’s Certifying Accountant
|
(b) Engagement of New Independent Registered Public Accounting
Firm.
On August 10, 2017, the Company engaged Eide Bailly LLP (“EB”) as its new independent registered public accounting
firm. The decision to engage EB was approved by the Audit Committee of the Company’s Board of Directors.
During the Company’s two most recent
fiscal years and in the subsequent interim period from January 1, 2017 through August 10, 2017, neither the Company nor anyone
acting on its behalf consulted with EB regarding any of the matters or events set forth in Item 304(a)(2) of Regulation S-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: August 14, 2017
|
CAPSTONE THERAPEUTICS CORP.
|
|
|
|
|
/s/ John M. Holliman, III
|
|
John M. Holliman, III
|
|
Executive Chairman
|
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Apr 2023 to Apr 2024